2 chapters across the catalog
The pharmaceutical industry faces a significant "patent cliff" in 2012 as major drugs like Lipitor lose patent protection. The hosts argue that the industry's heavy lobbying for SOPA was primarily aimed at shutting down international generic drug competition rather than protecting digital media.
Eli Lilly faces a significant "patent cliff" as several brand-name drugs lose market exclusivity through 2020. The discussion explores allegations that major pharmaceutical companies bribe generic manufacturers to delay the release of cheaper alternatives, allowing the original patent holders to maintain high prices.
